We could not find any results for:
Make sure your spelling is correct or try broadening your search.
The current ZYME market cap is 450.85M. The company's latest EPS is USD -1.6925 and P/E is -3.80.
Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Revenue | 2.63M | 402.49M | 35.58M | 7M | 16.51M |
Operating Income | -50.36M | 319.4M | -27.28M | -54.11M | -33.24M |
Net Income | -47.85M | 309.43M | -24.35M | -51.15M | -28.69M |
Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Revenue | 29.54M | 38.95M | 26.68M | 412.48M | 76.3M |
Operating Income | -150.53M | -187.47M | -215.63M | 130.53M | -137.76M |
Net Income | -145.44M | -180.55M | -211.84M | 124.34M | -118.67M |
Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Assets | 300.26M | 648.73M | 600.74M | 602.05M | 556.37M |
Total Liabilities | 120.51M | 155.77M | 127.21M | 153.14M | 132.02M |
Total Equity | 179.76M | 492.96M | 473.54M | 448.92M | 424.34M |
Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Assets | 368.21M | 538.38M | 389.13M | 648.73M | 580.88M |
Total Liabilities | 122.52M | 128.45M | 140.04M | 155.77M | 116.07M |
Total Equity | 245.68M | 409.92M | 249.09M | 492.96M | 464.81M |
Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Operating | -183.25M | 144.11M | -83.19M | -89.59M | -132.26M |
Investing | -31.78M | -53.85M | -138.22M | -198.9M | -205.92M |
Financing | 108.96M | 108.58M | 1.74M | 29.34M | 31.24M |
Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Operating | -81.85M | -151.4M | -192.45M | 144.11M | -118.3M |
Investing | -25.59M | -43.44M | 144.6M | -53.85M | -207.25M |
Financing | 193.66M | 308.98M | 8.01M | 108.58M | 81.85M |
Market Cap | 450.85M |
Price to Earnings Ratio | -3.80 |
Price to Sales Ratio | 5.91 |
Price to Cash Ratio | 2.86 |
Price to Book Ratio | 0.97 |
Dividend Yield | - |
Shares Outstanding | 70.12M |
Average Volume (1 week) | 0 |
Average Volume (1 Month) | 0 |
52 Week Change | - |
52 Week High | - |
52 Week Low | - |
Spread (Intraday) | 0.4 (5.97%) |
Company Name | Zymeworks Inc |
Address |
595 burrard street north vancouver, british columbia V7X 1L3 |
Website | https://www.zymeworks.com |
Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions